Tamoxifen is an excellent, highly effective standard therapy. Alternative options depend mainly on your menopausal status. For postmenopausal women, Aromatase Inhibitors (such as letrozole, anastrozole, or exemestane) are common alternatives. If you are premenopausal, combining hormone therapy with ovarian suppression is another option. Additionally, for certain higher-risk Stage II cases, newer targeted drugs like abemaciclib or olaparib can sometimes be added to your regimen to further reduce recurrence risk. Please discuss these options with your oncologist to see if any are appropriate for your specific pathology.

Stage 4 breast cancer is highly treatable, and many patients live active, fulfilling lives for years. While the average five-year survival rate is around 30%, individual outcomes vary greatly, and survival times are improving rapidly with newer therapies. Treatment focuses on controlling the cancer and maintaining quality of life. Key options include: Hormone therapies (like tamoxifen or letrozole) for hormone-receptor-positive cancers. Targeted therapies (such as trastuzumab or palbociclib).\n- Chemotherapy (like paclitaxel) to shrink tumours. Immunotherapy or radiation to manage specific areas.\n\nYour oncology team will customise a personalised plan tailored specifically to your cancer?s characteristics.